Clinical trial
Mucosal Healing Study in Crohn's Disease (CD)
NCT00297648 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00297648 |
|---|---|
| Title | Mucosal Healing Study in Crohn's Disease (CD) |
| Official title | A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease. |
| Acronym | MUSIC |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Certolizumab pegol |
| Enrollment | 89 |
| Start date | Feb 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Feb 28, 2006 |
| Last update posted | Aug 31, 2011 |
| Countries | Belgium, France, Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: